First French live-birth after oocyte vitrification performed before chemotherapy for fertility preservation
- 235 Downloads
We report the first French live birth after oocyte vitrification-thawing in a cancer survivor, and also the first live birth obtained by oocyte vitrification-thawing in a patient presenting premature ovarian failure (POF) after the treatment of a Hodgkin Lymphoma (HL). The patient gave her written consent for communication about the case.
The overall survival of patients with cancer has improved dramatically. Unfortunately, many treatments affect fertility; fertility preservation (FP) has become an important step in the management of young patients [1, 2]. In female patients, FP techniques indications depends on various parameters; vitrification of mature oocytes has emerged as an established method in the past years . Currently, in the context of FP before cancer treatment, dozens of live births have been published after ovarian cortex cryopreservation and subsequent grafting . Although oocyte vitrification is widely used in assisted reproductive techniques, it is...
KeywordsHodgkin Lymphoma Antral Follicle Fertility Preservation Premature Ovarian Failure Control Ovarian Stimulation
- 8.Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod Oxf Engl. 2011; 26(6):1270–83.Google Scholar
- 11.Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21(10):2052–60.CrossRefGoogle Scholar
- 17.Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98(1):141–4.CrossRefPubMedGoogle Scholar